AstraZeneca's Lynparza shown to put brakes on ovarian cancer
An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | Health | Ovarian Cancer | Ovaries